ABSTRACT
Lipid metabolism disorders in patients with end-stage renal disease, particularly in patients with nephrotic syndrome, were described by Dr Bright as long ago as 1827 [1]. It is known that patients with end-stage renal disease (ESRD) display a clinical picture of early accelerated (premature) atherosclerosis with severe cardiovascular and cerebral complications that are very often present even at a relatively early age compared with the general population. Today, it is considered that uraemic dyslipidaemia has persisted for many years before chronic dialysis treatment begins and presents a basic risk factor for an early start of the atherogenesic processes. That is why an analysis of apolipoprotein and lipid abnormalities as well as their etiopathogenetic mechanism in patients diseased with ESRD treated with repeated haemodialysis in the initiation phase of dialysis (the first 6 months), can clearly contribute to taking timely preventive measures (dietetic, healing) by which the frequency of apolipoprotein and lipid abnormalities will be decreased, which, at the same time, will result in reducing the processes of early atherosclerosis with all its complications in ESRD patients [2]. Disorders of apolipoprotein metabolism are considered as one of the most important factors for early atherosclerosis in patients with ESRD [3].
